Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/YIPF6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/YIPF6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/YIPF6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/YIPF6_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/YIPF6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
GO:00605763 | Esophagus | ESCC | intestinal epithelial cell development | 12/8552 | 14/18723 | 2.51e-03 | 1.08e-02 | 12 |
GO:0002066 | Esophagus | ESCC | columnar/cuboidal epithelial cell development | 29/8552 | 44/18723 | 5.41e-03 | 2.02e-02 | 29 |
GO:000206412 | Liver | Cirrhotic | epithelial cell development | 80/4634 | 220/18723 | 7.63e-05 | 8.44e-04 | 80 |
GO:000206422 | Liver | HCC | epithelial cell development | 114/7958 | 220/18723 | 3.19e-03 | 1.47e-02 | 114 |
GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
GO:00605762 | Oral cavity | OSCC | intestinal epithelial cell development | 10/7305 | 14/18723 | 1.44e-02 | 4.69e-02 | 10 |
GO:000206417 | Prostate | BPH | epithelial cell development | 85/3107 | 220/18723 | 3.16e-15 | 4.55e-13 | 85 |
GO:0060576 | Prostate | BPH | intestinal epithelial cell development | 8/3107 | 14/18723 | 6.63e-04 | 4.46e-03 | 8 |
GO:0060575 | Prostate | BPH | intestinal epithelial cell differentiation | 9/3107 | 23/18723 | 8.32e-03 | 3.60e-02 | 9 |
GO:000206418 | Prostate | Tumor | epithelial cell development | 88/3246 | 220/18723 | 1.30e-15 | 2.38e-13 | 88 |
GO:00605761 | Prostate | Tumor | intestinal epithelial cell development | 8/3246 | 14/18723 | 8.99e-04 | 5.96e-03 | 8 |
GO:00605751 | Prostate | Tumor | intestinal epithelial cell differentiation | 9/3246 | 23/18723 | 1.11e-02 | 4.56e-02 | 9 |
GO:000206427 | Thyroid | HT | epithelial cell development | 35/1272 | 220/18723 | 2.12e-06 | 7.61e-05 | 35 |
GO:00605764 | Thyroid | HT | intestinal epithelial cell development | 6/1272 | 14/18723 | 1.82e-04 | 2.68e-03 | 6 |
GO:00605752 | Thyroid | HT | intestinal epithelial cell differentiation | 7/1272 | 23/18723 | 6.13e-04 | 7.07e-03 | 7 |
GO:00020651 | Thyroid | HT | columnar/cuboidal epithelial cell differentiation | 14/1272 | 91/18723 | 3.23e-03 | 2.55e-02 | 14 |
GO:00020661 | Thyroid | HT | columnar/cuboidal epithelial cell development | 8/1272 | 44/18723 | 8.78e-03 | 4.95e-02 | 8 |
GO:0002064112 | Thyroid | PTC | epithelial cell development | 101/5968 | 220/18723 | 8.53e-06 | 9.74e-05 | 101 |
GO:000206428 | Thyroid | ATC | epithelial cell development | 103/6293 | 220/18723 | 3.06e-05 | 2.55e-04 | 103 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YIPF6 | SNV | Missense_Mutation | novel | c.28N>A | p.Asp10Asn | p.D10N | Q96EC8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.027) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
YIPF6 | SNV | Missense_Mutation | | c.445N>G | p.Gln149Glu | p.Q149E | Q96EC8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
YIPF6 | SNV | Missense_Mutation | | c.596N>T | p.Ser199Phe | p.S199F | Q96EC8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
YIPF6 | SNV | Missense_Mutation | rs763487554 | c.176N>A | p.Arg59His | p.R59H | Q96EC8 | protein_coding | tolerated(0.06) | possibly_damaging(0.489) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
YIPF6 | SNV | Missense_Mutation | novel | c.312N>T | p.Met104Ile | p.M104I | Q96EC8 | protein_coding | tolerated(0.36) | benign(0.017) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YIPF6 | SNV | Missense_Mutation | novel | c.100N>A | p.Val34Ile | p.V34I | Q96EC8 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
YIPF6 | SNV | Missense_Mutation | novel | c.301N>G | p.Leu101Val | p.L101V | Q96EC8 | protein_coding | tolerated(0.13) | possibly_damaging(0.838) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
YIPF6 | SNV | Missense_Mutation | novel | c.313C>A | p.Leu105Met | p.L105M | Q96EC8 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YIPF6 | SNV | Missense_Mutation | novel | c.133N>T | p.Arg45Cys | p.R45C | Q96EC8 | protein_coding | deleterious(0.05) | benign(0.145) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YIPF6 | SNV | Missense_Mutation | | c.289N>A | p.Leu97Ile | p.L97I | Q96EC8 | protein_coding | tolerated(0.17) | possibly_damaging(0.679) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |